Published in J Am Soc Nephrol on September 01, 2004
Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol (2011) 1.27
A new mouse model to explore therapies for preeclampsia. PLoS One (2010) 1.21
Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes (2008) 1.21
Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med (2008) 1.20
Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension (2011) 1.06
Microalbuminuria: causes and implications. Pediatr Nephrol (2011) 1.05
Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis (2008) 0.99
Relaxin as a natural agent for vascular health. Vasc Health Risk Manag (2008) 0.91
Endothelial factors and diabetic nephropathy. Diabetes Care (2011) 0.91
Molecular mechanisms of preeclampsia. J Pregnancy (2012) 0.90
Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med (2008) 0.86
Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med (2008) 0.84
The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? Am J Physiol Renal Physiol (2014) 0.83
Immunohistochemical expression of von Willebrand factor in the preeclamptic placenta. J Mol Histol (2011) 0.80
Effects of hyperhomocysteinemia on arterial pressure and nitric oxide production in pregnant rats. Am J Hypertens (2009) 0.79
Comparative Study of Endothelial Function and Uterine Artery Doppler Velocimetry between Pregnant Women with or without Preeclampsia Development. J Pregnancy (2012) 0.79
G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention. Hum Reprod Update (2016) 0.78
Vascular and cellular calcium in normal and hypertensive pregnancy. Curr Clin Pharmacol (2009) 0.78
Midterm eGFR and Adverse Pregnancy Outcomes: The Clinical Significance of Gestational Hyperfiltration. Clin J Am Soc Nephrol (2017) 0.78
Decreased expression and activation of Stat3 in severe preeclampsia. J Mol Histol (2015) 0.77
Role of lectin-like oxidized low density lipoprotein-1 in fetoplacental vascular dysfunction in preeclampsia. Biomed Res Int (2014) 0.76
Cost-effectiveness of recurrence risk guided care versus care as usual in women who suffered from early-onset preeclampsia including HELLP syndrome in their previous pregnancy (the PreCare study). BMC Pregnancy Childbirth (2010) 0.76
Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia. Inflamm Res (2011) 0.76
Brain cell apoptosis and enhancement of nervous excitability in pregnant rats with high plasma levels of homocysteine. Neural Regen Res (2012) 0.75
Poor periodontal health as a risk factor for development of pre-eclampsia in pregnant women. J Indian Soc Periodontol (2014) 0.75
Doppler ultrasound evaluation in preeclampsia. BMC Res Notes (2013) 0.75
Kidney Function Can Predict Pregnancy Outcomes. Clin J Am Soc Nephrol (2017) 0.75
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
The renal arterial resistance index and renal allograft survival. N Engl J Med (2003) 4.36
Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med (2009) 4.07
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Increased vascular smooth muscle contractility in TRPC6-/- mice. Mol Cell Biol (2005) 3.28
Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol (2012) 2.97
Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes. Kidney Int (2011) 2.94
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Weight loss and the renin-angiotensin-aldosterone system. Hypertension (2005) 2.58
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol (2002) 2.50
Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet (2004) 2.45
Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension (2004) 2.41
Long-term space flight simulation reveals infradian rhythmicity in human Na(+) balance. Cell Metab (2013) 2.38
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Periadventitial fat releases a vascular relaxing factor. FASEB J (2002) 2.29
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res (2007) 2.25
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens (2010) 2.23
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension (2007) 2.17
Retinol-binding protein 4 in human obesity. Diabetes (2006) 2.17
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation (2003) 2.15
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Acquired Brugada syndrome. Am J Cardiol (2003) 2.05
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Association between adiponectin and mediators of inflammation in obese women. Diabetes (2003) 2.05
Prorenin receptor is essential for podocyte autophagy and survival. J Am Soc Nephrol (2011) 2.04
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Long-term outcomes in acute renal failure patients treated with continuous renal replacement therapies. Am J Kidney Dis (2002) 2.01
Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats. Hypertension (2010) 2.01
Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension (2009) 2.00
Large-conductance calcium-activated potassium channel activity is absent in human and mouse neutrophils and is not required for innate immunity. Am J Physiol Cell Physiol (2007) 1.99
The sympathetic nervous system in hypertension: assessment by blood pressure variability and ganglionic blockade. J Hypertens (2003) 1.98
Phosphatidylinositol 3-kinase controls antineutrophil cytoplasmic antibodies-induced respiratory burst in human neutrophils. J Am Soc Nephrol (2002) 1.92
Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest (2013) 1.92
C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol (2008) 1.92
Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res (2004) 1.91
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res (2003) 1.89
Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension (2005) 1.89
Dysfunction of dysferlin-deficient hearts. J Mol Med (Berl) (2007) 1.89
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res (2002) 1.86
Autonomic nervous system and blood pressure regulation in RGS2-deficient mice. Am J Physiol Regul Integr Comp Physiol (2005) 1.84
Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids. J Biol Chem (2010) 1.83
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis (2010) 1.83
Nephrogenesis is induced by partial nephrectomy in the elasmobranch Leucoraja erinacea. J Am Soc Nephrol (2003) 1.83
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol (2010) 1.82
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol (2007) 1.80
Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens (2002) 1.79
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res (2005) 1.78
Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation (2009) 1.77
Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension (2005) 1.74
Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats. Am J Physiol Regul Integr Comp Physiol (2002) 1.72
Plasma exchange for primary autoimmune autonomic failure. N Engl J Med (2005) 1.71
Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. J Hypertens (2004) 1.71
Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol (2006) 1.70
Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes (2002) 1.70
Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol (2007) 1.69
The transcription factor grainyhead-like 2 regulates the molecular composition of the epithelial apical junctional complex. Development (2010) 1.68
Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract (2007) 1.67